Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 29-32 Weeks of Gestation

NCT01269528 is registered in ClinicalTrials.gov with Rambam Health Care Campus as lead sponsor.

NCT NCT01269528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01269528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 29-32 Weeks of Gestation
Lead sponsor
Rambam Health Care Campus
Phase
Observational
Overall status
Completed
Start date
August 31, 2013
Completion date
August 31, 2015
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bronchial hyperreactivity, infant, premature